Navigation Links
Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Date:8/19/2007

ainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO and VALSTAR(R); risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; need for additional funds and corporate partners, including for the development of our products; failure to acquire and develop additional product candidates; changes in reimbursement policies and/or rates for SANCTURA, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux- related litigation; the risk that the businesses of Indevus and Valera Pharmaceuticals, Inc. will not be integrated successfully during the period following the related merger; the risk that the cost savings and any other synergies from the merger may not be fully realized or may take longer to realize than expected; market acceptance for the merger and approved products; risks of regulatory review and clinical trials; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, futur
'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting
2. Indevus Reports Positive Data From Phase III NEBIDO Trial
3. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
4. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
5. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
6. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
7. Bipolar Disorder in Children Difficult to Diagnose, Reports the Harvard Mental Health Letter
8. First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A) Significantly Improves Idiopathic Detrusor Overactivity (IDO) in Patients With Symptoms of Overactive Bladder
9. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
10. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
11. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... - New Solution That Makes JINS MEME,s ... Co., Ltd. will launch JINS MEME "ACADEMIC PACK" in late ... $5,000 (without tax /including two pairs of JINS MEME and ... solution of "JINS MEME" to academic researchers, and it enables ... electrooculography and six-axis sensors without API. (*Physiological data that can ...
(Date:11/26/2014)... 26, 2014  Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... conferences. On Tuesday, December 2, the company ... Jaffray Healthcare Conference.  D. Keith Grossman , President ... the company beginning at 11:30 a.m., Eastern Standard Time ...
(Date:11/26/2014)... ANDOVER, Mass. , Nov. 26, 2014 /PRNewswire/ ... AEX: PHIA) today announced expanded availability of ... including DuraDiagnost, DigitalDiagnost, MobileDiagnost wDR, MobileDiagnost Opta[i] , ... of these solutions now available in the U.S., ... global markets, the portfolio offers Philips, customers innovative ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Thoratec Announces Presentations At Investor Conferences For December 2014 2Philips expands global reach of diagnostic X-Ray solutions 2Philips expands global reach of diagnostic X-Ray solutions 3
... Exceptionally high costs.  Long research and development cycles.  Low ...  Dependence on out-dated information technology options.  It,s not just ... information being wasted.   Such ... have led to the formation of a new company, ...
... -- XIANYANG, China, Aug. 17 /PRNewswire-Asia-FirstCall/ -- ... ... var ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
Cached Medicine Technology:RedOak Logic's Mission: Transform Pharmaceutical Industry Drug Development 2RedOak Logic's Mission: Transform Pharmaceutical Industry Drug Development 3RedOak Logic's Mission: Transform Pharmaceutical Industry Drug Development 4Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 2Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 3Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 4Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 5Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 6Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 7Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 8Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 9Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 10Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 11Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 12Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 13Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 14Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million 15
(Date:11/27/2014)... 2014 “Wekho” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers ... , An interesting new way to travel and experience the ... It’s called Wekho and it’s a free geolocation app ...
(Date:11/27/2014)... This is a professional and in ... an overview analysis, the report introduces Insulin basic ... industry overview, policy analysis, and news analysis, etc. ... information on policy, plans for Insulin Market product ... more. , This report also provides ...
(Date:11/27/2014)... 2014 At The Little Gym, we ... came as no surprise when a recent study confirmed ... success. The Journal of Pediatrics found that ... tasks during the school years may be important not ... The study monitored two groups of children; those that ...
(Date:11/27/2014)... 2014 The Emerald Cup 2014 Competition ... At This Year’s Entries | SKUNK Magazine – Proudly ... Two At Their Resort, Pure Garden, In Negril, Jamaica ... Hempcon, The Emerald Cup is presented by locals, for ... of California’s original cannabis industry." – SFGate, Smell The ...
(Date:11/27/2014)... November 27, 2014 In addition to ... an important gift home this holiday season and become ... disease. Visiting with relatives over the holidays may raise ... members. Although some change in cognitive ability can occur ... of normal aging. Recognizing the difference between normal aging ...
Breaking Medicine News(10 mins):Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:The Emerald Cup 2014 Competition Partners | CannCast – Bringing You An Up-Close Look At This Year’s Entries and SKUNK Magazine Proudly Sponsoring This Year's Grand Prize 2Health News:The Emerald Cup 2014 Competition Partners | CannCast – Bringing You An Up-Close Look At This Year’s Entries and SKUNK Magazine Proudly Sponsoring This Year's Grand Prize 3Health News:The Emerald Cup 2014 Competition Partners | CannCast – Bringing You An Up-Close Look At This Year’s Entries and SKUNK Magazine Proudly Sponsoring This Year's Grand Prize 4Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 2Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 3Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 4Health News:Alzheimer's Association Shares Tips to Navigate the Holiday Season 5
... Athens, Ga. - Pharmaceutical companies and universities are racing to ... RNA interference to treat a host of diseases. Now, a ... powerful tool: Researchers at the University of Georgia have demonstrated ... as a tool in the development of vaccines. , ...
... Dec. 10 /PRNewswire/ - Over 830 staff members are ... District,s newest fitness challenge. The 322 mile virtual race ... online challenge and it,s proving successful with less work ... Lee County School District has delivered fitness ...
... A University of British Columbia geneticist has discovered a gene ... uveal melanoma. , Catherine Van Raamsdonk, an assistant professor of ... team of researchers, have discovered a genetic mutation in a ... cent of the cases of uveal melanoma. , The findings, ...
... survey cites misperceptions regarding need for vaccination and a lack of ... , ... Bethesda, MD (PRWEB) December 10, 2008 -- A ... one-third (29.6 percent) have been vaccinated against the flu this season. ...
... superior to vitamin supplementation for cancer prevention. , ... ... of announcements two weeks ago that vitamin supplements A thru E ... more medical announcements with the same conclusions regarding prostate cancer. While ...
... 10 Markel Corporation is,pleased to announce the launch ... product. DataBreach(SM) helps businesses manage,risk associated with their reliance ... in their custody or care. , ... the increase in identity theft,that has been plaguing businesses ...
Cached Medicine News:Health News:Study first to show that RNA interference can facilitate vaccine development 2Health News:Study first to show that RNA interference can facilitate vaccine development 3Health News:Lee County School District online wellness program inspires employees to walk 200 million steps in 2 months 2Health News:UBC researchers discover gene mutation that causes eye cancer 2Health News:Mid-Season Flu Immunization Rates are Too Low 2Health News:Mid-Season Flu Immunization Rates are Too Low 3Health News:Mid-Season Flu Immunization Rates are Too Low 4Health News:Mid-Season Flu Immunization Rates are Too Low 5Health News:Treadmill Desks More Effective in Decreasing Prostate Cancer Risks Than Vitamin and Antioxidant Supplements 2Health News:Markel Corporation Announces New DataBreach(SM) Privacy Liability Coverage 2
... For treatment of carpal tunnel syndrome, mild ... following cast removal. The perforated suede ... the wrist, wicking away moisture for long ... metal splint prevents painful wrist flexion, and ...
... orthotic elbow system that can be used in ... proximal ulnar fractures or post reconstructive surgery where ... highly flexible system that provides you with a ... that best fits your patients needs. Two ...
A lightweight soft good with rigid elbow protection. Designed by medical professionals with your needs in mind. Provides elbow stability for mild to moderate medial/lateral and hyperextension injurie...
Worn by many professional athletes, EpiTrain is our most popular elbow support....
Medicine Products: